Ironwood Pharmaceuticals Cl A: (NASD: IRWD)

$12.91

-0.58 (-4.30%)

Volume 6,675,447

May 22 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		12.65 - 13.65
	
		52wk Low - High
		10.01 - 19.67
	
		Previous Close
		13.49
	
		Avg. Volume
		1,105,916
	
		Industry
		MED-DRUGS
	
		Market Cap
		1.46 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.90
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-2.81
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		108 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -2.81
                        
                            Current Quarter Estimate
                            -0.72
                        
                            Most Accurate Estimate
                            -0.72
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-16-2013
                        
                            EPS Last Year
                            -1.24
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.   
Full IRWD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
IRWD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.72	-0.65	-2.81	-1.63
Number of Estimates	7	7	8	7
Low Estimate	-0.89	-0.74	-3.04	-1.95
High Estimate	-0.64	-0.54	-2.57	NA
Year Ago EPS	-0.38	0.42	-0.68	-2.81
EPS Growth	-90.23%	-254.08%	-313.60%	41.94%

More IRWD Estimates

Average Earnings Estimates for IRWD

EPS Growth for IRWD

Industry Analysis

Name	Symbol	Previous Close
IRONWOOD PHARMA	IRWD	13.49
JAZZ PHARMACEUT	JAZZ	60.00
SALIX PHARM-LTD	SLXP	59.33
SANTARUS INC	SNTS	22.30
USANA HLTH SCI	USNA	67.95
BIOCRYST PHARMA	BCRX	1.70
CATALYST PHARMA	CPRX	0.91
CELL THERAPEUT	CTIC	1.32
CUBIST PHARM	CBST	55.46
ELAN CP PLC ADR	ELN	12.07

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Loss Widens at Ironwood

Apr 24, 2013

Loss Widens at IRWD on Higher Costs

Jan 16, 2013

Alkermes Maintains Fiscal 2013 View

Jan 09, 2013

Forest Settles with Glenmark

Jan 09, 2013

Catalyst-Filled 2013 for Onyx

Jan 09, 2013

Upbeat 2013 from ViroPharma

Jan 08, 2013

Cubist Reports Impressive 4Q Sales

Jan 08, 2013

Ironwood Winds Up Debt Offering

Jan 07, 2013

More IRWD Zacks Commentary

Financials

EPS TTM	-1.24
Sales	150
Net Income	-131
Price/Earnings	NA
Price/Book	24.89
Price/Cash Flow	NA
Price/Sales	10.31

More IRWD Financials

News

Ironwood Pharmaceuticals prices $136.5 million public offering of common stock - Datamonitor Financial Deals Tracker

May 22, 2013

Benzinga`s Top Pre-Market Losers - Benzinga

May 21, 2013

Ironwood Pharmaceuticals Prices Public Offering of Common Stock - Businesswire

May 21, 2013

Ironwood Pharmaceuticals announces public offering of common stock - Datamonitor Financial Deals Tracker

May 21, 2013

Ironwood Pharmaceuticals Announces 10.5M Share Proposed Public Offering of Common Stock - Benzinga

May 20, 2013

Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock - Businesswire

May 20, 2013

Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2013 - Businesswire

May 14, 2013

Ironwood Pharmaceuticals to Present Corporate Overview at BofA Merrill Lynch 2013 Health Care Conference - Close-Up Media

May 12, 2013

See All News Stories on IRWD

Broker Recommendations

Current ABR	3.00
ABR (Last Week)	3.00
# of recs in ABR	9
Average Target Price	15.61
Industry Rank by ABR	108 out of 265
Rank in Industry	16 out of 93

More IRWD Broker Recommendations

Day Low - High	12.65 - 13.65
52wk Low - High	10.01 - 19.67
Previous Close	13.49
Avg. Volume	1,105,916
Industry	MED-DRUGS
Market Cap	1.46 B
Div - Yield	0.00 - 0.00
Beta	0.90
PE (Forward)	0.00
Current Year Est.	-2.81
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-2.81
Current Quarter Estimate	-0.72
Most Accurate Estimate	-0.72
Earnings ESP	0.00%
Next Earnings Report Date	07-16-2013
EPS Last Year	-1.24
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Ironwood Pharmaceuticals Cl A: (NASD: IRWD)

$12.91

-0.58 (-4.30%)

Volume 6,675,447

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations